These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24650011)

  • 1. Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.
    Tamari R; Schinke C; Bhagat T; Roth M; Braunschweig I; Will B; Steidl U; Verma A
    Leuk Lymphoma; 2014 Dec; 55(12):2901-6. PubMed ID: 24650011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
    Will B; Kawahara M; Luciano JP; Bruns I; Parekh S; Erickson-Miller CL; Aivado MA; Verma A; Steidl U
    Blood; 2009 Oct; 114(18):3899-908. PubMed ID: 19710504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome.
    Mavroudi I; Pyrovolaki K; Pavlaki K; Kozana A; Psyllaki M; Kalpadakis C; Pontikoglou C; Papadaki HA
    Leuk Res; 2011 Mar; 35(3):323-8. PubMed ID: 20688394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.
    Pathak S; Roth M; Verma A; Steidl U
    Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1667-75. PubMed ID: 24215532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The new thrombopoietic agenda: impact on leukemias and MDS.
    Bussel JB
    Best Pract Res Clin Haematol; 2014; 27(3-4):288-92. PubMed ID: 25455280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag.
    Erickson-Miller CL; Kirchner J; Aivado M; May R; Payne P; Chadderton A
    Leuk Res; 2010 Sep; 34(9):1224-31. PubMed ID: 20202683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.
    Fang J; Liu X; Bolanos L; Barker B; Rigolino C; Cortelezzi A; Oliva EN; Cuzzola M; Grimes HL; Fontanillo C; Komurov K; MacBeth K; Starczynowski DT
    Nat Med; 2016 Jul; 22(7):727-34. PubMed ID: 27294874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro.
    He X; Dou A; Feng S; Roman-Rivera A; Hawkins C; Lawley L; Zhang J; Wunderlich M; Mizukawa B; Halene S; Patel A; Fang J
    Exp Hematol; 2020 Jun; 86():21-27.e2. PubMed ID: 32437909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.
    Chesnais V; Renneville A; Toma A; Lambert J; Passet M; Dumont F; Chevret S; Lejeune J; Raimbault A; Stamatoullas A; Rose C; Beyne-Rauzy O; Delaunay J; Solary E; Fenaux P; Dreyfus F; Preudhomme C; Kosmider O; Fontenay M;
    Blood; 2016 Feb; 127(6):749-60. PubMed ID: 26626993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML.
    Shastri A; Verma AK
    Lancet Haematol; 2018 Jan; 5(1):e6-e7. PubMed ID: 29241763
    [No Abstract]   [Full Text] [Related]  

  • 12.
    D'Alò F; Zangrilli I; Cupelli E; Fianchi L; Criscuolo M; Falconi G; Fabiani E; Pagano L; Hohaus S; De Stefano V
    Platelets; 2021 Apr; 32(3):378-382. PubMed ID: 32268817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
    Rollison DE; Shain KH; Lee JH; Hampras SS; Fulp W; Fisher K; Al Ali NH; Padron E; Lancet J; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Dalton W; List A; Komrokji RS
    Cancer Med; 2016 Jul; 5(7):1694-701. PubMed ID: 27098006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial.
    Gonzalez-Lugo JD; Kambhampati S; Yacoub A; Donnellan WB; Berdeja J; Bhagat P; Fehn K; Remy C; Jasra S; Kazemi M; Pradhan K; Kim M; Mantzaris I; Sica RA; Shah N; Goldfinger M; Kornblum N; Gritsman K; Braunschweig I; Steidl U; Will B; Shastri A; Verma A
    Clin Cancer Res; 2023 Jan; 29(1):60-66. PubMed ID: 36255372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
    Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
    Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure.
    Swaminathan M; Borthakur G; Kadia TM; Ferrajoli A; Alvarado Y; Pemmaraju N; Bodden K; Yearby B; Konopleva M; Khoury J; Bueso-Ramos C; Garcia-Manero G; DiNardo CD
    Leuk Lymphoma; 2019 Sep; 60(9):2207-2213. PubMed ID: 30773968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltrombopag for treatment of thrombocytopenia-associated disorders.
    Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
    Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.